![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Humana Inc | NYSE:HUM | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
9.29 | 2.56% | 372.27 | 388.57 | 370.00 | 371.99 | 2,217,773 | 20:30:32 |
Humana Inc. (NYSE: HUM) today reported consolidated pretax results and net earnings per share (EPS) for the quarter ended March 31, 2024 (1Q24) versus the quarter ended March 31, 2023 (1Q23) as noted in the tables below.
Consolidated income before income taxes and equity in net earnings (pretax results) In millions
1Q24 (a)
1Q23 (a)
Generally Accepted Accounting Principles (GAAP)
$1,014
$1,614
Amortization associated with identifiable intangibles
16
18
Put/call valuation adjustments associated with company's non-consolidating minority interest investments
131
53
Transaction and integration costs
—
(51
)
Change in fair market value of publicly-traded equity securities
—
(1
)
Impact of exit of employer group commercial medical products business
1
(81
)
Value creation initiatives
29
—
Adjusted (non-GAAP)
$1,191
$1,552
Net earnings per share (EPS)
1Q24 (a)
1Q23 (a)
GAAP
$6.11
$9.87
Amortization associated with identifiable intangibles
0.13
0.14
Put/call valuation adjustments associated with company's non-consolidating minority interest investments
1.08
0.42
Transaction and integration costs
—
(0.41
)
Change in fair market value of publicly-traded equity securities
—
(0.01
)
Impact of exit of employer group commercial medical products business
0.01
(0.64
)
Value creation initiatives
0.24
—
Tax impact of non-GAAP adjustments
(0.34
)
0.01
Adjusted (non-GAAP)
$7.23
$9.38
Refer to the "Footnotes" section included herein for further explanation on disclosures for Adjusted (non-GAAP) financial measures, as well as additional reconciliations.
Please refer to the tables above, as well as the consolidated and segment highlight sections in the detailed earnings release for additional discussion of the factors impacting the year-over-comparisons.
In addition, a summary of key consolidated and segment statistics comparing 1Q24 to 1Q23 follows.
Humana Inc. Summary of Results ($ in millions, except per share amounts)
1Q24 (a)
1Q23 (a)
CONSOLIDATED
Revenues
$29,611
$26,742
Revenues - Adjusted (non-GAAP)
$29,332
$25,652
Pretax results
$1,014
$1,614
Pretax results - Adjusted (non-GAAP)
$1,191
$1,552
EPS
$6.11
$9.87
EPS - Adjusted (non-GAAP)
$7.23
$9.38
Benefit ratio
88.9
%
85.5
%
Benefit ratio - Adjusted (non-GAAP)
88.9
%
85.9
%
Operating cost ratio
10.4
%
11.2
%
Operating cost ratio - Adjusted (non-GAAP)
10.2
%
10.9
%
Operating cash flows
$423
$6,687
Operating cash flows - Adjusted (non-GAAP) (b)
$423
$38
Parent company cash and short term investments
$509
$909
Debt-to-total capitalization
45.1
%
41.1
%
Days in Claims Payable (DCP)
42.5
41.2
INSURANCE SEGMENT
Revenues
$28,699
$25,903
Revenues - Adjusted (non-GAAP)
$28,420
$24,814
Benefit ratio
89.3
%
86.1
%
Benefit ratio - Adjusted (non-GAAP)
89.4
%
86.4
%
Operating cost ratio
8.3
%
9.4
%
Operating cost ratio - Adjusted (non-GAAP)
8.2
%
9.0
%
Income from operations
$898
$1,327
Income from operations - Adjusted (non-GAAP)
$903
$1,252
CENTERWELL SEGMENT
Revenues
$4,818
$4,505
Operating cost ratio
93.0
%
91.6
%
Income from operations
$282
$330
Income from operations - Adjusted (non-GAAP) (c)
$335
$379
Refer to the "Footnotes" section included herein for further explanation on disclosures for Adjusted (non-GAAP) financial measures, as well as reconciliations.
FY 2024 Earnings Guidance
Humana revised its GAAP EPS guidance for the year ending December 31, 2024 (FY 2024) to approximately $13.93 from approximately $14.87, while affirming its Adjusted EPS guidance of approximately $16.00.
Diluted earnings per common share
FY 2024 Guidance (d)
GAAP
approximately $13.93
Amortization of identifiable intangibles
0.49
Put/call valuation adjustments associated with company's non-consolidating minority interest investments
1.08
Impact of exit of employer group commercial medical products business
0.90
Value creation initiatives
0.24
Cumulative net tax impact of non-GAAP adjustments
(0.64
)
Adjusted (non-GAAP) – FY 2024 projected
approximately $16.00
Refer to the "Footnotes" section included herein for further explanation on disclosures for Adjusted (non-GAAP) financial measures, as wellas additional reconciliations.
Detailed Press Release
Humana’s full earnings press release, including the statistical pages, has been posted to the company’s Investor Relations site and may be accessed at https://humana.gcs-web.com/ or via a current report on Form 8-K filed by the company with the Securities and Exchange Commission this morning (available at www.sec.gov or on the company’s website).
Conference Call
Humana will host a live question and answer session for analysts at 9:00 a.m. Eastern time today to discuss its financial results for the quarter and the company’s expectations for future earnings. In advance of the question and answer session, Humana will post prepared management remarks to the Quarterly Results section of its Investor Relations page (https://humana.gcs-web.com/financial-information/quarterly-results).
To participate via phone, please register in advance at this link - https://register.vevent.com/register/BI6d7513be1a494bbb82b4b8caa62d3b2f.
Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique registrant ID that can be used to access the call.
A webcast of the 1Q24 earnings call may also be accessed via Humana’s Investor Relations page at humana.com. The company suggests participants for both the conference call and those listening via the web dial in or sign on at least 15 minutes in advance of the call.
For those unable to participate in the live event, the archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page (https://humana.gcs-web.com/events-and-presentations), approximately two hours following the live webcast.
Footnotes
The company has included financial measures throughout this earnings release that are not in accordance with GAAP. Management believes that these measures, when presented in conjunction with the corresponding GAAP measures, provide a comprehensive perspective to more accurately compare and analyze the company’s core operating performance over time. Consequently, management uses these non-GAAP (Adjusted) financial measures as consistent and uniform indicators of the company’s core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Non-GAAP (Adjusted) financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP. All financial measures in this earnings release are in accordance with GAAP unless otherwise indicated. Please refer to the footnotes for a detailed description of each item adjusted out of GAAP financial measures to arrive at non-GAAP (Adjusted) financial measures.
(a) For the periods covered in this earnings press release, the following items are excluded from the non-GAAP financial measures described above, as applicable:
1Q24
1Q23
Insurance segment
$4
$6
CenterWell segment
$12
$12
In addition to the reconciliations shown on pages 1 and 2 of this release, the following are reconciliations of GAAP to Adjusted (non-GAAP) measures described above and disclosed within this earnings release:
Revenues
Revenues - CONSOLIDATED
(in millions)
1Q24
1Q23
GAAP
$29,611
$26,742
Change in fair market value of publicly-traded equity securities
—
(1
)
Impact of exit of employer group commercial medical products business
(279
)
(1,089
)
Adjusted (non-GAAP)
$29,332
$25,652
Revenues - INSURANCE SEGMENT
(in millions)
1Q24
1Q23
GAAP
$28,699
$25,903
Impact of exit of employer group commercial medical products business
(279
)
(1,089
)
Adjusted (non-GAAP)
$28,420
$24,814
Benefit Ratio
Benefit ratio - CONSOLIDATED
1Q24
1Q23
GAAP
88.9
%
85.5
%
Impact of exit of employer group commercial medical products business
—
%
0.4
%
Adjusted (non-GAAP)
88.9
%
85.9
%
Benefit ratio - INSURANCE SEGMENT
1Q24
1Q23
GAAP
89.3
%
86.1
%
Impact of exit of employer group commercial medical products business
0.1
%
0.3
%
Adjusted (non-GAAP)
89.4
%
86.4
%
Operating Cost Ratio
Operating cost ratio - CONSOLIDATED
1Q24
1Q23
GAAP
10.4
%
11.2
%
Impact of exit of employer group commercial medical products business
(0.1
)%
(0.3
)%
Value creation initiatives
(0.1
)%
—
%
Adjusted (non-GAAP)
10.2
%
10.9
%
Operating cost ratio - INSURANCE SEGMENT
1Q24
1Q23
GAAP
8.3
%
9.4
%
Impact of exit of employer group commercial medical products business
(0.1
)%
(0.4
)%
Adjusted (non-GAAP)
8.2
%
9.0
%
Income from Operations
Income from operations - INSURANCE SEGMENT
1Q24
1Q23
GAAP
$898
$1,327
Amortization associated with identifiable intangibles
$4
$6
Impact of exit of employer group commercial medical products business
1
(81
)
Adjusted (non-GAAP)
$903
$1,252
(b) Generally, when the first day of a month falls on a weekend or holiday, with the exception of January 1 (New Year's Day), the company receives its monthly Medicare premium payment from CMS on the last business day of the previous month. On a GAAP basis, this can result in certain quarterly cash flows from operations including more or less than three monthly payments. Consequently, when this occurs, the company reports Adjusted cash flows from operations to reflect three payments in each quarter to match the related expenses.
Net cash from operating activities
(in millions)
1Q24
1Q23
GAAP
$423
$6,687
Timing of premium payment from CMS
—
(6,649
)
Adjusted (non-GAAP)
$423
$38
(c) The CenterWell segment Adjusted income from operations includes an adjustment to add back depreciation and amortization expense to the segment's GAAP income from operations since such an adjustment is commonly utilized for valuation purposes within the healthcare delivery industry.
Income from operations - CENTERWELL SEGMENT
(in millions)
1Q24
1Q23
GAAP
$282
$330
Depreciation and amortization expense
53
49
Adjusted (non-GAAP)
$335
$379
(d) FY 2024 projected Adjusted results exclude the future impact of items that cannot be estimated at this time.
Cautionary Statement
This news release includes forward-looking statements regarding Humana within the meaning of the Private Securities Litigation Reform Act of 1995. When used in investor presentations, press releases, Securities and Exchange Commission (SEC) filings, and in oral statements made by or with the approval of one of Humana’s executive officers, the words or phrases like “expects,” “believes,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions are intended to identify such forward-looking statements.
These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the “Risk Factors” section of the company’s SEC filings, a summary of which includes but is not limited to the following:
In making forward-looking statements, Humana is not undertaking to address or update them in future filings or communications regarding its business or results. In light of these risks, uncertainties, and assumptions, the forward-looking events discussed herein may or may not occur. There also may be other risks that the company is unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.
Humana advises investors to read the following documents as filed by the company with the SEC for further discussion both of the risks it faces and its historical performance:
About Humana
Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424638477/en/
Lisa Stoner Humana Investor Relations (502) 580-2652 e-mail: LStamper@humana.com Mark Taylor Humana Corporate Communications (317) 753-0345 e-mail: MTaylor108@humana.com
1 Year Humana Chart |
1 Month Humana Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions